Limula receives CHF 0.5 million FIT loan to expand its Technology Access Program – Limula
Summary
Credit: NIAID CC BY 2.0 Limula is a fast-growing Life Science Tools company combining Swiss Made precision engineering and Cell and Gene Therapy expertise to deliver next-generation manufacturing platform. Despite the demonstrated clinical benefit, the complex, manual and costly production methods available to the industry remain an important barrier to successful and at scale commercialisation after market approval.CGT manufacturing automation company Limula announces today it has received a loan of half a million Swiss francs from the Fondation pour lInnovation et la technologie (FIT), complementing a Seed round the company closed earlier in the year. Having the capacity to expand the pool of early adopters will greatly benefit Limula by providing additional feedback during a critical product design phase.Limula was founded in 2020 by Dr. Luc Henry together with Dr. Yann Pierson and Dr. Thomas Eaton to deliver a disruptive approach to the ex vivo manipulation of immune and haematopoietic stem cells, leveraging a completely novel technology concept designed with the particularities of CGT manufacturing in mind. Limula offers a totally novel approach to cell processing automation, based on a simple yet unique invention, combining a bioreactor and a centrifuge in a single system for the first time. Their cell processing platform leverages a proprietary design and automation to bring all functionalities required for on-demand and at-scale manufacturing of cell therapies in a single device.Active since 1994, the Fondation pour lInnovation et la technologie (FIT) provides financial support to early-stage companies based in the Canton de Vaud in Switzerland and developing innovative products in energy & environment, information & digital technologies, life sciences & health, precision industries, and nutrition & agri-food.